Dr. Davis has over 18 years of experience in industry, focused on protein and antibody engineering, bispecific and multispecific antibody platform development, and drug discovery in a wide range of therapeutic areas. Prior to joining Invenra, Dr. Davis was a Principal Scientist at Bristol-Myers Squibb, where he worked on all aspects of biologic drug design, including successfully designing a trispecific HIV biotherapeutic. Before that he worked at EMD Serono, where he developed novel biologic drug platforms. Dr. Davis was a post-doctoral fellow at Harvard Medical School, and earned a Ph.D. in Biophysics from Univ. of Cal. San Francisco and a B.A. in music from Reed College.
Of the over 200 different bispecific antibody platforms that have been described, those that mimic IgGs are of particular interest, due to their well validated format, standard manufacturing techniques, and tunable features such as effectors and half life. Here we present the Invenra bispecific platform, and describe several different ways it can be used effectively as either agonist or cytotoxic agent. These approaches are generalizable to other similar platforms, and add new functionality that is not attainable with a monoclonal antibody.